|
AUPO755097A0
(en)
*
|
1997-06-25 |
1997-07-17 |
University Of Queensland, The |
Receptor agonist and antagonist
|
|
AUPQ339899A0
(en)
|
1999-10-13 |
1999-11-04 |
University Of Queensland, The |
Novel molecules
|
|
CN1231464C
(zh)
|
2000-08-10 |
2005-12-14 |
三菱制药株式会社 |
新型3－取代的脲衍生物及其药学应用
|
|
WO2002022556A1
(en)
|
2000-09-14 |
2002-03-21 |
Mitsubishi Pharma Corporation |
Novel amide derivatives and medicinal use thereof ugs
|
|
AUPR833401A0
(en)
*
|
2001-10-17 |
2001-11-08 |
University Of Queensland, The |
G protein-coupled receptor antagonists
|
|
JP4290564B2
(ja)
|
2002-03-19 |
2009-07-08 |
チルドレンズ ホスピタル メディカル センター |
Ｃ５ａアナフィラトキシンの突然変異タンパク質、このような突然変異タンパク質をコードする核酸分子ならびにＣ５ａアナフィラトキシンの突然変異タンパク質の医薬的使用
|
|
JP2005530719A
(ja)
*
|
2002-03-29 |
2005-10-13 |
ニューロジェン コーポレーション |
病原性炎症要素を有する状態の治療のための組み合わせ療法
|
|
AUPS160602A0
(en)
*
|
2002-04-08 |
2002-05-16 |
University Of Queensland, The |
Therapeutic method
|
|
AU2002950657A0
(en)
|
2002-08-08 |
2002-09-12 |
Alchemia Limited |
Derivatives of monosaccharides for drug discovery
|
|
AU2003266858B2
(en)
*
|
2002-10-11 |
2006-09-14 |
Vast Bioscience Pty Limited |
Classes of compounds that interact with GPCRs
|
|
AU2002951995A0
(en)
|
2002-10-11 |
2002-10-31 |
Alchemia Limited |
Classes of compounds that interact with gpcrs
|
|
AU2002952086A0
(en)
*
|
2002-10-16 |
2002-11-07 |
The University Of Queensland |
Treatment of osteoarthritis
|
|
ATE509632T1
(de)
*
|
2002-10-16 |
2011-06-15 |
Promics Pty Ltd |
Behandlung von entzündlicher darmerkrankung
|
|
AU2002952129A0
(en)
*
|
2002-10-17 |
2002-10-31 |
The University Of Queensland |
Treatment of hypersensitivity conditions
|
|
AU2003902354A0
(en)
*
|
2003-05-15 |
2003-05-29 |
Harkin, Denis W. |
Treatment of haemorrhagic shock
|
|
AU2003902586A0
(en)
*
|
2003-05-26 |
2003-06-12 |
The University Of Queensland |
Treatment of burns
|
|
WO2005014849A2
(en)
*
|
2003-07-03 |
2005-02-17 |
Euro-Celtique, S.A. |
Genes associated with responses to neuropathic pain
|
|
EP1498422A1
(de)
*
|
2003-07-17 |
2005-01-19 |
Jerini AG |
C5a-Rezeptor-Antagonisten
|
|
CA2579678A1
(en)
*
|
2004-10-04 |
2006-04-13 |
Alchemia Limited |
Selective inhibitors
|
|
AU2006205830A1
(en)
*
|
2005-01-17 |
2006-07-20 |
Jerini Ag |
C5a receptor antagonists
|
|
DE602006019948D1
(de)
*
|
2005-03-11 |
2011-03-17 |
Potentia Pharmaceuticals Inc |
Koppelten rezeptors zur behandlung von makuladegeneration
|
|
EP1739078A1
(de)
|
2005-05-30 |
2007-01-03 |
Jerini AG |
C5a-Rezeptor-Antagonisten
|
|
US20070292421A1
(en)
*
|
2005-07-28 |
2007-12-20 |
Feinberg Bruce B |
Method for treating preeclampsia
|
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
|
AU2008214359B2
(en)
|
2007-02-05 |
2014-01-16 |
Apellis Pharmaceuticals, Inc. |
Local complement inhibition for treatment of complement-mediated disorders
|
|
US20110092446A1
(en)
*
|
2007-07-20 |
2011-04-21 |
Cedric Francois |
Compositions and methods for treatment of trauma
|
|
WO2009121065A2
(en)
*
|
2008-03-28 |
2009-10-01 |
Apellis Ag |
Modulation and repletion/enhancement of the complement system for treatment of trauma
|
|
JP2011526738A
(ja)
*
|
2008-07-02 |
2011-10-13 |
サンゴバン・パフォーマンス・プラスティックス・シェンヌー |
枠付き装置、封止材およびその製造方法
|
|
US9447176B2
(en)
|
2008-11-10 |
2016-09-20 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating complement-associated disorders
|
|
EP2525814A4
(en)
*
|
2010-01-22 |
2013-09-11 |
Univ Louisville Res Found |
METHOD FOR THE TREATMENT OR PREVENTION OF PARODONTITIS AND DISORDERS ASSOCIATED WITH PARODONTITIS
|
|
JP6022441B2
(ja)
|
2010-04-30 |
2016-11-09 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
抗Ｃ５ａ抗体およびその抗体の使用のための方法
|
|
US9895411B2
(en)
*
|
2010-06-29 |
2018-02-20 |
San Diego State University Research Foundation |
Analogs of C5a and methods of using same
|
|
EP2468295A1
(en)
|
2010-12-21 |
2012-06-27 |
Affiris AG |
Vaccines based on peptides of the complement protein C5a
|
|
EP2723361B1
(en)
|
2011-06-22 |
2019-10-30 |
Apellis Pharmaceuticals, Inc. |
Methods of treating chronic disorders with complement inhibitors
|
|
US9289467B2
(en)
|
2011-08-10 |
2016-03-22 |
Case Western Reserve University |
Compositions and methods for treating bone conditions
|
|
WO2014043223A1
(en)
*
|
2012-09-11 |
2014-03-20 |
Hospital For Special Surgery |
Irhom2 inhibition for the treatment of complement mediated disorders
|
|
EP3929206A1
(en)
|
2012-11-15 |
2021-12-29 |
Apellis Pharmaceuticals, Inc. |
Long-acting compstatin analogs and related compositions and methods
|
|
US10308687B2
(en)
|
2013-03-15 |
2019-06-04 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
|
AU2014248252A1
(en)
*
|
2013-04-02 |
2015-10-29 |
M. Reza Ghadiri |
Uses of cyclic peptides for treating and preventing atherosclerosis
|
|
SI3011345T1
(sl)
|
2013-08-07 |
2017-12-29 |
Alexion Pharmaceuticals, Inc. |
Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
|
|
CA3287719A1
(en)
|
2015-10-07 |
2026-03-02 |
Apellis Pharmaceuticals, Inc. |
Use of long-acting compstatin analog for treating a complement-mediated disorder
|
|
MA45770A
(fr)
|
2016-07-29 |
2019-06-05 |
Pfizer |
Peptides cycliques en tant qu'antagonistes du récepteur c5
|
|
WO2018081400A1
(en)
|
2016-10-27 |
2018-05-03 |
Alexion Pharmaceuticals Inc. |
Assay for c5b-9 deposition in complement-associated disorders
|
|
EP3978523A1
(en)
|
2017-04-03 |
2022-04-06 |
InflaRx GmbH |
Treatment of inflammatory diseases with inhibitors of c5a activity
|
|
CN116059313A
(zh)
|
2017-04-07 |
2023-05-05 |
阿佩利斯制药有限公司 |
给药方案以及相关组合物和方法
|
|
CN111201241A
(zh)
|
2017-06-23 |
2020-05-26 |
因弗拉克斯有限责任公司 |
用C5a活性抑制剂治疗炎性疾病
|
|
KR20240167712A
(ko)
|
2017-12-15 |
2024-11-27 |
아펠리스 파마슈티컬스 인코포레이티드 |
투여 요법 및 관련 조성물 및 방법
|
|
US20220356234A1
(en)
|
2019-10-02 |
2022-11-10 |
Alexion Pharmaceuticals, Inc. |
Complement inhibitors for treating drug-induced complement-mediated response
|
|
BR112022019090A2
(pt)
|
2020-03-27 |
2022-11-08 |
Inflarx Gmbh |
Inibidores de c5a para o tratamento de infecção por coronavírus
|
|
TW202208427A
(zh)
|
2020-05-06 |
2022-03-01 |
德商因夫萊亞斯有限公司 |
人源化抗ｃ５ａ抗體
|
|
EP4150338A1
(en)
|
2020-05-15 |
2023-03-22 |
Alexion Pharmaceuticals, Inc. |
Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
|
|
WO2024238422A1
(en)
|
2023-05-12 |
2024-11-21 |
Alexion Pharmaceuticals, Inc. |
Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles
|
|
WO2024238421A1
(en)
|
2023-05-12 |
2024-11-21 |
Alexion Pharmaceuticals, Inc. |
Use of biomarkers for the identification and treatment of complement-mediated disorders
|
|
US12180274B2
(en)
|
2023-05-26 |
2024-12-31 |
Inflarx Gmbh |
Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
|